 Rhythm Pharmaceuticals Inc NASDAQ: RYTM will modify its Phase 3 EMANATE and ongoing Phase 2 DAYBREAK trials of setmelanotide in rare genetic diseases of obesity Recent FDA feedback indicated that additional clinical trials to support potential registration for non-rare patient. 